Ember Therapeutics Inc. (EMBT) 0.6500 $EMBT Emb
Post# of 273242
Posted On: 09/19/2016 7:17:54 PM
Ember Therapeutics Inc. (EMBT) 0.6500 $EMBT
Ember Therapeutics Acquires Dermasilk(TM) Brands
GlobeNewswire - Mon Sep 12, 1:48PM CDT
Ember Therapeutics, Inc. (OTCQB:EMBT), a diversified New York-based pharmaceutical company developing targeted therapies for osteoarthritis, kidney fibrosis, and other regenerative medicines, today announced that it has entered into a definitive agreement for the acquisition of Dermasilk(TM) Brands, a commercially available over-the-counter beauty product portfolio encompassing fourteen different products. The products are currently sold at several large retailers including Rite-Aid, CVS, Wal-Mart and K-Mart.
Ember Therapeutics to Present at Marcum MicroCap Conference
GlobeNewswire - Tue May 31, 12:31PM CDT
Ember Therapeutics, Inc. (OTCQB:EMBT), a New York-based biopharmaceutical company developing targeted therapies for osteoarthritis, kidney fibrosis, and other indications using Bone Morphogenetic Protein (BMP)-7, today announced that the Company is scheduled to present at the 2016 Marcum MicroCap Conference being held June 1-2, 2016 in New York, NY.
Ember Therapeutics Acquires Dermasilk(TM) Brands
GlobeNewswire - Mon Sep 12, 1:48PM CDT
Ember Therapeutics, Inc. (OTCQB:EMBT), a diversified New York-based pharmaceutical company developing targeted therapies for osteoarthritis, kidney fibrosis, and other regenerative medicines, today announced that it has entered into a definitive agreement for the acquisition of Dermasilk(TM) Brands, a commercially available over-the-counter beauty product portfolio encompassing fourteen different products. The products are currently sold at several large retailers including Rite-Aid, CVS, Wal-Mart and K-Mart.
Ember Therapeutics to Present at Marcum MicroCap Conference
GlobeNewswire - Tue May 31, 12:31PM CDT
Ember Therapeutics, Inc. (OTCQB:EMBT), a New York-based biopharmaceutical company developing targeted therapies for osteoarthritis, kidney fibrosis, and other indications using Bone Morphogenetic Protein (BMP)-7, today announced that the Company is scheduled to present at the 2016 Marcum MicroCap Conference being held June 1-2, 2016 in New York, NY.
(0)
(0)Scroll down for more posts ▼